News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
EPL will supply APR approved 100% recyclable and fully sustainable Platina Tubes for the toothpaste category of Unilever
Adjusted PAT declined 18.8% YoY
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Financial support is being provided as a grant from the Government of India
Subscribe To Our Newsletter & Stay Updated
